Access

Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in genomics, we have the obligation to drive down the cost of sequencing, expand access to diagnostics technology, and increase the diversity of genomics data to realize health equity for billions of people around the world.

Videos from this campaign

Stephanie Lheureux, MD, PhD,Princess Margaret Cancer Centre (PMCC).
Illumina Booth at UK Festival of Genomics & Biodata

Content from this campaign

Health & Healthcare

Illumina Supports Norway's Pioneering Precision Medicine Study
Illumina, Inc. (NASDAQ:ILMN), announced that it is supporting a national precision medicine study in Norway to assess the efficacy of blood-based comprehensive genomic profiling (CGP) in cancer therapy selection testing.

Innovation & Technology

Early Cancer Detection for Dogs Is Here
In early 2019, Daniel Grosu found himself dealing with compounding personal crises: he had relocated his parents, who were both recently diagnosed with cancer, from Arizona so they could receive care at the University of California, San Diego (UCSD).

Sustainable Finance & Socially Responsible Investment

Illumina and Sequoia Capital China Select First Startups to Join Genomics Incubator in China
Illumina, Inc. (NASDAQ: ILMN), and Sequoia Capital China, a leading investment firm, today jointly announced the selection of the first two startup companies joining the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.

Health & Healthcare

Illumina and Genetic Alliance Launch $120 Million Global Initiative to Increase Equity and Improve Outcomes for Families Impacted by Genetic Disease
Illumina, Inc. (NASDAQ: ILMN) and Genetic Alliance today announced the creation of the iHope™ Genetic Health program aimed at providing whole-genome sequencing access (WGS) to tens of thousands of patients across the globe impacted by genetic disease.

Health & Healthcare

Illumina Supports Canada's Nationwide COVID-19 Genome Sequencing Initiative
Illumina Inc. (NASDAQ: ILMN) today announced that its world-class sequencing and bioinformatics solutions are being used by HostSeq, part of the Canadian COVID-19 Genomics Network (CanCOGeN), to identify biomarkers that can help predict potential risk of serious disease and support the development of novel therapeutics to combat COVID-19.

Health & Healthcare

Illumina Supports Israel's National Program to Accelerate Diagnoses of Critically-Ill Newborns with Suspected Genetic Disease
Illumina, Inc. (NASDAQ: ILMN) announced an agreement with Israel's Ministry of Health (MoH) for a pilot program to implement the use of whole-genome sequencing (WGS) in critically-ill infants suspected of having a genetic disorder in neonatal intensive care units (NICU).

Health & Healthcare

"Pharmacogenomics Saved My Life"
“My family won the genetic bipolar lottery,” says Mehri Coulter, 36, of Boise, Idaho. “My great-grandma, grandma, mom, sister, and nephew had or have bipolar.”

Health & Healthcare

On World Cancer Research Day, Illumina Highlights the Transformative Power of Genomics
Cancer is a devastating disease that is quickly becoming the leading cause of death worldwide. In 2020, there were nearly 10 million cancer deaths around the globe.

Health & Healthcare

Illumina's Spotlight on Ovarian Cancer: Understanding Tumors Through Comprehensive Genomic Profiling
“Growing up, I had a fear of being broadsided. The idea of an out-of-nowhere collision that might kill or maim me was terrifying. I grew out of this fear and while I’ve never been in that kind of accident, I have been repeatedly broadsided by cancer for the past 11 years.”

Responsible Business & Employee Engagement

Illumina Ventures Closes $325 Million Fund Supporting Start-ups in Healthcare Innovation
Illumina Ventures, an independently-managed, healthcare-focused venture firm, announced today the closing of its second investment fund with total commitments of $325 million, bringing its total capital under management to $560 million.
Illumina logo

More from Illumina

  1. Business
    At Illumina, the faster we can innovate, the more lives we can help save. As a genomics pioneer, we have proven through focused and continued...

  2. People
    Harnessing the world’s best talent and giving them the opportunity to thrive allows us to make world-changing leaps in human health and beyond. Our...

  3. Access
    Genomics should be available to the many, not the few. It has the power to save lives and vastly improve the human condition. As the leader in...

  4. Community
    By sharing our time, talent, and technology, we aim to inspire, support, and empower our communities, our employees, and the next generation.

  5. Environment
    We are committed to integrating environmental stewardship into the way we operate. We recognize the importance of the environment in creating a...

  6. Operating Responsibly
    Our role as a genomics pioneer brings with it the responsibility to enable innovation for good, ensuring that the technology we create and the data we...